Sirtris Pharmaceuticals and Sirtuin Academic Thought Leaders Publish Review on the Therapeutic Potential of Sirtuins for Disease
16 August 2007 - 10:00PM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging, announced today that Sirtris, together
with leading sirtuin researchers David A Sinclair, Ph.D. and
Leonard P. Guarente, Ph.D., published a review in the MIT Tech
Review entitled �Developing Drugs to Treat Diseases of Aging.� The
review highlights the discovery of sirtuins, a novel class of
enzymes, and their role in the aging process. Additionally, the
article discusses the drug development path of SIRT1 activators as
potential treatments for a range of diseases of aging including
metabolic disorders such as Type 2 Diabetes, mitochondrial
disorders such as MELAS, neurological disorders, and cancer. �This
review summarizes the growing body of evidence regarding the
substantial therapeutic potential of SIRT1 activators, such as
SRT501, our proprietary formulation of resveratrol, and new
chemical entities which are 1000 times more potent than
resveratrol, to address a broad range of diseases of aging,� said
Christoph Westphal, M.D., Ph.D., Chief Executive Officer of Sirtris
Pharmaceuticals, Inc. David A. Sinclair, Ph.D. is a scientific
co-founder, member of the Board of Directors of Sirtris
Pharmaceuticals, Associate Professor of Pathology at Harvard
Medical School, and Director of the Glenn Laboratories for the
Biological Mechanisms of Aging. Leonard P. Guarente is the Novartis
Professor of Biology at the Massachusetts Institute of Technology.
The article can be accessed at:
http://www.technologyreview.com/Biotech/19238/ About Sirtris
Pharmaceuticals Sirtris Pharmaceuticals is a biopharmaceutical
company focused on discovering and developing proprietary, orally
available, small molecule drugs with the potential to treat
diseases associated with aging, including metabolic diseases such
as Type 2 Diabetes. Our drug candidates are designed to mimic
certain beneficial health effects of calorie restriction, without
requiring a change in eating habits, by activation of sirtuins, a
recently discovered class of enzymes that control the aging
process. The company's headquarters are in Cambridge,
Massachusetts. This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, the potential therapeutic effects of SIRT1 activators for
multiple neurodegenerative diseases and other types of disorders,
the progress and results of pre-clinical studies of SIRT1
activators, and the potential of sirtuin modulators to receive
regulatory approval. These forward-looking statements about future
expectations, plans and prospects of Sirtris Pharmaceuticals
involve significant risks, uncertainties and assumptions, including
risks related to the lack of results that would provide a basis for
predicting whether any of the Company�s product candidates will be
safe or effective, or receive regulatory approval, the possibility
that results of pre-clinical studies are not necessarily predictive
of clinical trial results, the Company's potential inability to
initiate and complete pre-clinical studies and clinical trials for
its product candidates, the fact that none of the Company's product
candidates has received regulatory approvals, the potential
inability of the�Company to gain market acceptance of the Company's
product candidates, and those other risks factors�that can be found
in the�Company's filings with the Securities and Exchange
Commission. Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Sierra Natl BK Tehachapi Calif (MM) (NASDAQ): 0 recent articles
More Sirtris Pharmaceuticals, Inc. News Articles